Company intelligence / Profile preview
Guangzhou Virotech Pharmaceutical
Guangzhou, Guangdong, Chinavirot.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Guangzhou Virotech’s lead asset, recombinant oncolytic virus M1 (VRT106/M1-c6v1), is in Phase 1 clinical trials for solid tumors. The company has a robust patent portfolio and focuses on first-in-class/best-in-class virotherapies with intravenous delivery and companion diagnostics. No published clinical efficacy data yet; early-stage results focus on safety/tolerability[3][5][9].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusRecombinant protein
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
none publicly disclosed as of June 2025
Beyond the preview
Go deeper on Guangzhou Virotech Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Virotech Pharmaceutical.